ArticleBMJ open respiratory research2019
The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference.
Article in BMJ open respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Comparative efficacy of different types of structured exercise interventions for idiopathic pulmonary fibrosis: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2020Pooled it
- Effect of Remote Vital Signs Monitoring in People Receiving Long-Term Oxygen Therapy: Protocol for a Randomized Controlled Trial.JMIR research protocols · 2026Trial
- Improved quality of life, reduced quantitative lung fibrosis in a trial of inhaled pirfenidone for idiopathic pulmonary fibrosis.BMC pulmonary medicine · 2026Trial
- Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trial.Journal of translational medicine · 2022Trial
- Inspiratory muscle training enhances recovery post-COVID-19: a randomised controlled trial.The European respiratory journal · 2022Trial
- Trial
- Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis.Respiratory research · 2020Trial
- Effect of home-based pulmonary rehabilitation in patients with interstitial lung disease in a tertiary care centre - A randomized controlled trial.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Expanding Remote Patient Monitoring for Pre-Lung Transplant Candidates With Interstitial Lung Disease.Clinical transplantation · 2026Article
- Functional, radiological and survival outcomes in rheumatoid arthritis-associated interstitial lung disease: 24-month results from the BERTHA prospective cohort.BMJ open respiratory research · 2026Article
- Systemic Sclerosis-Associated ILD: Insights and Limitations of ScleroID.Diagnostics (Basel, Switzerland) · 2026Article
- A randomised clinical trial of a digital self-management package for people with interstitial lung disease: the REBUILD-SM protocol.Respiratory research · 2025Article
- Quality of life in patients with hypersensitivity pneumonitis and with idiopathic pulmonary fibrosis in real-life clinical practice.Journal of thoracic disease · 2025Article
- Health-related quality of life measured with K-BILD is associated with survival in patients with idiopathic pulmonary fibrosis.BMC pulmonary medicine · 2024Article
- Article
- Article
- Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report.American journal of respiratory and critical care medicine · 2024Article
- Clinical Impact of Physical Activity and Cough on Disease Progression in Fibrotic Interstitial Lung Disease.Journal of clinical medicine · 2023Article
- Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.BMC pulmonary medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
Abstract
Introduction: The King's Brief Interstitial Lung Disease (KBILD) is a 15-item validated health-related quality of life (HRQOL) questionnaire. The method of scoring the KBILD has recently changed to incorporate a logit-scale transformation from one that used raw item responses, as this is potentially a more linear scale. The aim of this study was to re-evaluate the KBILD minimal clinically important difference (MCID) using the new logit -transformed scoring. Methods: 57 patients with interstitial lung disease (17 idiopathic pulmonary fibrosis, IPF) were asked to complete the KBILD questionnaire on two occasions in outpatient clinics. At the second visit, patients also completed a 15-item global rating of change of health status questionnaire (GRCQ). The MCID was calculated as the mean of four different methods: the change in KBILD for patients indicating a small change in GRCQ, patients with a 7%-12% change in FVC, 1 SE of measurement of baseline KBILD and effect size (ES) of 0.3. Results: The mean (SD) KBILD total score for all patients was 55.3 (15.6). 16 patients underwent a therapeutic intervention. 36 patients reported a change in their condition on the GRCQ; 22 deteriorated, 14 improved and 21 were unchanged. There was a significant change in KBILD total score in patients reporting a change in GRCQ; mean (SD) 57.0 (13.6) versus 50.0 (9.7); mean difference 7.0; 95% CI of difference 3.0 to 11.0; p<0.01. The change in KBILD total score correlated with the GRCQ scale; r=-0.49, p<0.01. The mean KBILD total score MCID was 5. The MCID of KBILD domains were 6 for Psychological, 7 for Breathlessness and Activities, and 11 for Chest Symptoms. Conclusion: The KBILD is a responsive tool for longitudinal assessment of HRQOL in patients with ILD. The MCID of the KBILD total score is a 5-unit change.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.